IMMUNOCORE HOLDINGS PLC-ADR

IMCR12 Dec 2024
Healthcare
$31.95
-0.03 (-3.39%)
Lowest Today
$30.09
Highest Today
$32.53
Today’s Open
$31.95
Prev. Close
$31.85
52 Week High
$76.98
52 Week Low
$29.72
To Invest in IMMUNOCORE HOLDINGS PLC-ADR

IMMUNOCORE HOLDINGS PLC-ADR

Healthcare
IMCR12 Dec 2024
-0.03 (-3.39%)
1M
3M
6M
1Y
5Y
Low
$30.09
Day’s Range
High
$32.53
30.09
52 Week Low
$29.72
52-Week Range
52 Week High
$76.98
29.72
1 Day
-
1 Week
-0.35%
1 month return
-8.64%
3 month return
-6.57%
6 month return
-24.02%
1 Year return
-50.17%
3 Years return
+2.45%
5 Years return
-
10 Years return
-
Institutional Holdings
Wellington Management Company LLP
14.09
T. Rowe Price Investment Management,Inc.
12.99
RTW INVESTMENTS, LLC
9.73
FMR Inc
9.67
Vanguard Health Care Inv
9.16
PRIMECAP Management Company
4.94
T. Rowe Price Associates, Inc.
4.31

Market Status

Fundamentals
Market Cap
1593.54 mln
PB Ratio
4.22
PE Ratio
0
Enterprise Value
1173.32 mln
Total Assets
597 mln
Volume

Company Financials

Fund house & investment objective

Company Information
Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.
Organisation
IMMUNOCORE HOLDINGS PLC-ADR
Employees
497
Industry
Biotechnology
CEO
Dr. Bahija  Jallal Ph.D.
Trading and brokerage services provided by
Technology Services provided by Motilal Oswal Financial Services:

Take your next step